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ABSTRACT
Objectives: To evaluate the effect of the PROPER intervention in nursing home residents with dementia on the
prevalence of psychotropic drug use and neuropsychiatric symptoms.
Design: A cluster-randomized controlled design with two parallel groups (intervention versus usual care) and
assessments at 0, 6, 12, and 18months.
Setting: Thirty-one dementia special care units within 13 long-term care organizations in the Netherlands.
Participants: Three hundred eighty nursing home residents with dementia
Intervention: The PROPER intervention consisted of a structured and repeated multidisciplinary medication
review, supported by education and continuous evaluation.
Measurements: Prescriptions of antipsychotics, antidepressants, anxiolytics, and hypnotics, and occurrence of
neuropsychiatric symptoms.
Results: The prescription of any type of psychotropic drugs increased in the intervention group, and decreased
in the control group, with an estimated difference of 3.9 percentage points per 6 months (p= 0.01). Effects for
the individual drug groups were minor (differences of 1.6 percentage points and below per 6 months) and not
statistically significant. The occurrence of neuropsychiatric symptoms remained stable in both the intervention
and control groups during the follow-up of 18months.
Conclusions: The PROPER intervention failed to demonstrate effectiveness in reducing the prevalence of
psychotropic drugs. It may be interesting to enrich the intervention with components that address personal
attitudes and communication between nursing home professionals, not only with respect to the prescription of
psychotropic drugs, but also to neuropsychiatric symptoms.
The study has been registered in The Netherlands Trial Register (NTR3569).
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Introduction
Neuropsychiatric symptoms are highly prevalent
in people with dementia, especially among
those who live in long-term care organizations
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(Selbaek et al., 2013). These symptoms are fre-
quently treated with psychotropic drugs, despite
limited efficacy and enlarged risks of side effects,
particularly for antipsychotics (Ballard and Waite,
2006). Since the late eighties, trials have been
conducted to improve the prescription of psycho-
tropic drugs for nursing home residents. These trials
varied in focus (e.g. medication review, involvement
of pharmacists and/or nurses, education), geograph-
ical location and results, and their implementation
varied (Avorn et al., 1992; Ballard et al., 2016; Crotty
et al., 2004; Fossey et al., 2006; Ray et al., 1987; Tjia
et al., 2015; Westbury et al., 2010).
In the Netherlands, nursing home care for people
with dementia is organized differently than in most
countries. Those people reside at dementia special
care units (DSCUs), and medical care is usually
provided by physicians who have been educated as
elderly care physicians and are employed by the
nursing home, and by nurses (Koopmans et al.,
2017). Nursing education is divided into five levels,
which we consider comparable with nursing assis-
tant (level 1 and 2), certified nursing assistant
(level 3), and registered nurse (level 4 and 5).
When prescribing psychotropic drugs, these physi-
cians can make use of the Guideline for problem
behavior of theDutch body representing elderly care
physicians (Verenso) (Smalbrugge et al., 2008).
Despite differences in care, psychotropic drugs are
prescribedwith similar prevalence rates compared to
other Western European countries (Janus et al.,
2016).
In order to improve the prescription of psycho-
tropic drugs, we developed the PROPER interven-
tion. This intervention has several key elements.
First, it consists of a medication review with a
structured and repeated design. Second, it uses a
multidisciplinary approach. Aside from the elderly
care physician and a pharmacist, a nurse (assistant)
is also present. Nurses are expected to add insights
on the residents’ neuropsychiatric symptoms and
side effects, in addition to the medical and pharma-
cological knowledge. Third, the intervention is
largely based on the above-mentioned Guideline
for problem behavior, and the Multidisciplinary
guideline Polypharmacy in the Elderly (Nederlands
Huisartsen Genootschap, 2012; Smalbrugge et al.,
2008).
This manuscript reports on secondary outcomes
of the PROPER II trial. The primary outcome, the
Appropriate Psychotropic Drug use In Dementia
index, showed that the PROPER intervention
improved the appropriateness of prescription for
those psychotropic drugs that were prescribed
(van der Spek et al., 2018a). The current study is
conducted at the resident level. It aims to evaluate
the effect of the PROPER intervention in nursing
home residents with dementia on (1) the prevalence
of psychotropic drug use prescribed for neuropsy-
chiatric symptoms (e.g. antipsychotics, antidepres-
sants, hypnotics, and anxiolytics) and on (2) the
occurrence of neuropsychiatric symptoms.
Methods
Design and setting
This study was part of the PROPER II trial, as
described in detail elsewhere (Smeets et al., 2013).
We used a cluster-randomized controlled design with
two parallel groups (intervention versus usual care)
and assessments at 0, 6, 12, and 18months.
Participants
All residents living in the participating DSCUs were
eligible for inclusion if they had a chart diagnosis
of dementia. Participants who dropped out were
replaced by residents who were newly admitted to
the participating DSCUs.
Intervention
We developed a method for a structured and
repeated multidisciplinary medication review sup-
ported by education and continuous evaluation.
The method consisted of three components: (1)
preparation and education, followed by a cycle of
(2) conduct, and (3) evaluation/guidance.
The first component included preparation of
organizational aspects, such as assignment of a
coordinator, division of tasks, and planning. It
also included education of physicians, pharmacists,
and nurses on how to conduct medication reviews,
and on benefits and harms of psychotropic drugs.
The education was provided by the Dutch Institute
for Rational Use of Medicine (IVM) (Instituut
VerantwoordMedicijngebruik). It prescribes adher-
ence to the Guideline for problem behavior of the
Dutch Association of Elderly Care Physicians, and
the Multidisciplinary guideline Polypharmacy in the
Elderly (including the Systematic Tool to Reduce
Inappropriate Prescribing [STRIP], the Screening
Tool to Alert doctors to Right Treatment [START],
and the Screening Tool of Older Person’s potentially
inappropriate Prescriptions [STOPP]) (Gallagher
et al., 2008; Nederlands Huisartsen Genootschap,
2012; Smalbrugge et al., 2008).
The second component comprised the actual
conduct and follow-up of the medication review
by the (elderly care) physician, pharmacist, and a
nurse (assistant). Prior to the medication review,
each of the participants had to prepare within his or
her field of expertise, that is, to respectively obtain
medical information, pharmacological information,
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and knowledge on the resident’s current behavior
and presence of potential side effects. During a
medication review meeting, the participants dis-
cussed the start, continuation, discontinuation, or
dose change of psychotropic and other drugs, as well
as additional diagnostics and alternative interven-
tions for the management of neuropsychiatric symp-
toms. Potential changes and actions were registered
and proposed to the resident’s representative and
followed up by the physician and nurse.
The third component consisted of evaluation
meetings on the process of the medication reviews.
Positive experiences and benefits, as well as points
for improvement, were shared during these meet-
ings. They were attended by the participants
of the medication reviews and guided by the IVM.
If participants had questions in between the meet-
ings, the IVM was available by means of an online
helpdesk.
Assessments
The prescription of psychotropic drugs was assessed
as the prescription of one or more drugs from the
Anatomical Therapeutic Chemical group of anti-
psychotics (N05A), antidepressants (N06A), anxio-
lytics (N05B), hypnotics (N05C), and any of these
four groups (Nordic Council on Medicines, 1990).
Psychotropic drugs had to be prescribed for neuro-
psychiatric symptoms explained by the presence of
dementia, for a sleep disorder, or for a delirium.
Also, psychotropic drugs for which no indication
could be found were registered. Pro re nata prescrip-
tions were excluded, since the actual use could not
reliably be collected.
Neuropsychiatric symptoms were assessed using
the Neuropsychiatric Inventory – Questionnaire
(NPI-Q) and the Cohen-Mansfield Agitation Inven-
tory (CMAI) (Cohen-Mansfield et al., 1989; Kaufer
et al., 2000). The NPI-Q consists of 12 neuropsy-
chiatric symptom items and gives a total severity
score ranging from 0 to 36 (with a higher score
indicating higher severity) and a total distress score
ranging from 0 to 60 (with a higher score indicating
higher caregiver distress). We also analyzed the
scores for the clusters “psychosis” and “agitation”,
and for the symptoms “nighttime symptoms”,
“anxiety”, “apathy”, and “depressive symptoms”
(Zuidema et al., 2011). The CMAI includes 29
items on physical aggression, physically nonaggres-
sive behavior, and verbal agitation, and ranges from
29 to 203 (with a higher score indicating more
frequent agitation).
We collected the following baseline characteris-
tics: age, sex, chart type of dementia, and length
of stay at the DSCU. We also assessed the stage of
dementia using the Global Deterioration Scale
(GDS) ranging from 1 to 7 (with a higher stage
reflecting more severe dementia) (Reisberg et al.,
1982).
Data on the prescription of psychotropic drugs,
age, sex, type of dementia, and length of stay were
collected from medical files and medication lists by
researchers. Data on neuropsychiatric symptoms
were completed via web-based questionnaires by
nurses who were directly involved in the residents’
care. The web-based GDS questionnaires were
completed by the residents’ physicians. Participants
were not directly involved in the study. Assessments
were conducted at baseline, and after 6, 12, and
18months.
Cluster randomization
Randomization to either the intervention group or to
the care-as-usual group was conducted at organiza-
tional level to avoid contamination of the interven-
tion to the control group. There was no blinding in
this study. Allocation was computer-generated and
conducted by a statistician.
DSCU and participant selection
In line with the sample size calculation of the pri-
mary outcome, we included the 12 organizations
that had participated in the previously conducted
PROPER I study, supplemented with an additional
organization to account for potential dropout of an
organization (Smeets et al., 2013). From each orga-
nization, we randomly selected two DSCUs, and
from each DSCU 15 residents. If a DSCU had less
than 15 residents, we included 1 or more additional
DSCUs in order to reach at least 30 residents per
organization.
Statistical analysis
First, data on psychotropic drugs and neuropsychi-
atric symptoms were aggregated on DSCU level in
order to analyze psychotropic drug prevalence rates
and mean NPS. Although the use of psychotropic
drugs was binary, it was our focus to diminish the
DSCU averages of percentage prescriptions (i.e. a
population-averages as opposed to subject-specific
estimates). Therefore, we aimed at interpretation of
differences in percentage points. Subsequently, we
used linear mixed models with identity links to
account for repeated measurements within DSCUs,
which were again nested within organizations. Orga-
nization and DSCU were considered random
effects, and time (continuous) and treatment and
their interaction as fixed effects. Themodel assumed
equal baseline values, because of the randomization,
and we expected the averages to be normally dis-
tributed. We assessed model fit by checking if the
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residuals were normally distributed, and by check-
ing the residuals of the mixed models and the
observed-versus-predicted-value plots. All analyses
were conducted intention-to-treat with IBM SPSS
Statistics for Windows, Version 22.0 (Armonk, NY:
IBM Corp.).
Sensitivity analyses
In the process evaluation of this trial, we have seen
that one intervention organization did not fully
adhere to the intervention procedures: the pharma-
cist was absent for the education, for some of the
medication review meetings and for all evaluation
meetings; and the coordinator could not conduct
all organizational tasks (Gerritsen et al., 2019). Also,
three control organizations had already conducted
medication reviews with a nurse throughout the
trial. We conducted two sensitivity analyses to
gain further insight into these process evaluation
findings.
Ethics
The local Medical Ethics Review Committee
“CMO Regio Arnhem-Nijmegen” rated the study
(number 2012/226) and stated that it was in accor-
dance with the applicable Dutch rules concerning
review of research ethics committees and informed
consent. We followed the principles of the Declara-
tion of Helsinki (WorldMedical Association, 2013).
The representatives of the residents on the partici-
pating DSCUs were informed about the study in
writing and given the explicit opportunity to refrain
from the resident’s participation. The study has
been registered in The Netherlands Trial Register
(NTR3569).
Results
The study was conducted from September 2012 to
July 2014. We included 13 long-term care organiza-
tions, which were located throughout the Nether-
lands. Seven organizations were randomly assigned
to the intervention group and six to continue care as
usual. One organization in the intervention group
withdrew after the baseline assessment due to depar-
ture of the coordinating physician. In the interven-
tion group, the mean number of participants per
DSCUwas 12, 11, 14, and 13 at baseline, 6, 12, and
18months, respectively, overall range 6 to 20. In the
control group, this number was 16 residents (at all
assessments), overall range 4 to 19. There were 21
physicians involved in the intervention group, with
turnover in all organizations. In the control group,
there were 14 other physicians involved, with turn-
over in half of the organizations.
Participant flow
A total of 380 residents were included. In the inter-
vention group, 170 participants dropped out (143
due to death, transfer to another unit, no diagnosis
of dementia was found in charts by the researchers,
or withdrawal during the study and 27 due to the
withdrawal of the organization) and were replaced
by 120 new residents versus 90 dropouts and 83
replacements in the control group. A total of 323
residents completed the final assessment, 186 of
whom participated from baseline onward (92 in
intervention and 94 in the control group). Details
are shown in Figure 1.
Baseline characteristics
Table 1 presents the baseline characteristics. In
the intervention group, the proportion of partici-
pants with Alzheimer’s dementia was higher
versus a higher proportion of vascular and other
dementia in the control group. The intervention
population had slightly more severe dementia,
having the GDS mode at stage 6 versus at stage 5
in the control group. There were no other baseline
imbalances.
Effect
Table 2 shows the observed DSCU means for the
different variables, which are also described below.
Amixedmodel with linear trend for the intervention
and control groups showed a good fit to the data.
Therefore, the effect of the intervention was esti-
mated as the difference in slopes per 6 months with
95% confidence intervals.
PSYCHOTROPIC DRUG PRESCRIPTION
The observed prevalence of any psychotropic drug
prescription increased by 5 percentage points (SD
22) from baseline to the final assessment in the
intervention group and decreased by 8 percentage
points (SD 13) in the control group. The model
estimated difference between the slopes for use of
any psychotropic drug increased by 3.9 percentage
points every 6 months (p= 0.01). Prescription of
antipsychotics in the intervention group was
observed to decrease by 5 percentage points (SD
20) from baseline to 12months, but then to increase
again by 4 percentage points (SD 6). In the control
group, the antipsychotic prescription consistently
was observed to decrease by a total of 5 percentage
points (SD 11) from baseline to 18months. Antide-
pressant or hypnotic prescriptions did not change in
the intervention group and was observed to decrease
in the control group by 2 (SD 15) and 3 percentage
points (SD 10), respectively. The prescription of
anxiolytics was observed to increase by 4 percentage
580 C.H.W. Smeets et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1041610220000629
Downloaded from https://www.cambridge.org/core. Radboud University Nijmegen, on 22 Jul 2021 at 07:32:47, subject to the Cambridge Core terms of use, available at
points (SD 12) in the intervention group and to
decrease by 1 percentage point (SD 9) in the control
group. Slope differences of the individual drug
groups as estimated by the model were small (1.6
percentage points and below) and not statistically
significant.
NEUROPSYCHIATRIC SYMPTOMS
Neuropsychiatric symptoms assessed by the NPI-Q
remained rather constant and did not show statisti-
cally significant slope differences. Also, in the NPI
cluster and symptom scores (psychosis, agitation,
nighttime symptoms, anxiety, apathy, and depres-
sive symptoms), differences were not statistically
significant (results not shown in table). Agitation
assessed with the CMAI was observed to increase
slightly by 2.6 points (SD 15.5) in the intervention
group and by 0.5 points (SD 10.0) in the control
group, leading to a small, but not statistically
significant estimated slope difference of 0.6 every
6 months.
Sensitivity analyses
Table 3 shows the results of the sensitivity analyses.
If we excluded the organization that did not fully
adhere to the intervention procedures from the
analyses, results were similar. If we excluded the
control organizations that conducted medication
reviews with a nurse as usual care, the decline in
the prescription of any psychotropic drugs and sub-
sequently the slope difference was even greater and
remained statistically significant.
Discussion
We found that the PROPER intervention did not
reduce the prescription of antipsychotics, antide-
pressants, hypnotics, nor anxiolytics for neuropsy-
chiatric symptoms in nursing home residents with
dementia. The prescription of psychotropic drugs
increased in the intervention group, whereas it
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Figure 1. Flow chart.
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neuropsychiatric symptoms remained stable. Results
were consistent when we excluded data from the
organization that did not fully adhere to the interven-
tion procedures, and from organizations in the con-
trol group that carried out similar medication reviews
as part of their usual care. This implies that it is
disputable whether the PROPER intervention is an
effective tool for reducing the prescription of psycho-
tropic drugs.
When interpreting the results, we are able to
differentiate between two potential sources for the
negative effectiveness: trial conduct and the inter-
vention’s design.
Trial conduct
First, the dropout rate in the intervention group was
almost twice as high as in the control group. Although
this was partly due to dropout of one organization,
there was still a substantially higher dropout after
baseline in the intervention group. Assuming that this
was not a result of the intervention, it may very well
have biased the effect of the intervention. For
instance, the influx of new residents is likely to
have missed the effect of the first medication review
round, whereas the effect on prescriptions for parti-
cipants that died between the assessments is not
included. In general, it could very well be that
changes in the case mix of the study population
had more impact on the prescription rates than
the intervention. Reflections of these changes may
be visible in the fluctuations between the different
assessments and may even be accountable for the
negative effectiveness.
Second, we were unable to operationalize the
correction for the occurrence of neuropsychiatric
symptoms throughout the study in the analyses.
Knowing that neuropsychiatric symptoms are the
most important factor for prescription of psychotro-
pic drugs, wewould have preferred to include these in
ourmodel (Smeets et al., 2017).However, this would
have raised the issue of how to operationalize this
correction. The total NPI score for instance includes
Table 1. Baseline characteristics
CHARACTERISTIC INTERVENTION CONTROL
.............................................................................................................................................................................................................................................................................................
Number of participants 222 158
Age in years [SD] (range) 84 [7.4] (55–99) 83 [7.3] (55–99)
Sex N (%)
Female 173 (78%) 114 (72%)
Male 49 (22%) 44 (28%)
Type of dementia, N (%)
Alzheimer’s dementia 90 (41%) 37 (23%)
Vascular dementia 27 (12%) 29 (18%)
Mixed Alzheimer’s/vascular dementia 22 (10%) 19 (12%)
Other dementia 83 (37%) 73 (46%)
GDS N (%)
Stage 2 0 (0%) 1 (1%)
Stage 3 4 (2%) 5 (3%)
Stage 4 15 (7%) 19 (12%)
Stage 5 47 (21%) 53 (34%)
Stage 6 74 (33%) 41 (26%)
Stage 7 48 (22%) 27 (17%)
Unknown 34 (15%) 12 (8%)
Length of stay at DSCU in months [SD] (range) 25 [21.8] (0–118) 24 [21.7] (0–114)
Psychotropic drug prescription, N (%)
Any* 107 (48%) 81 (51%)
Antipsychotics 56 (25%) 33 (21%)
Antidepressants 56 (25%) 40 (25%)
Hypnotics 31 (14%) 18 (11%)
Anxiolytics 32 (14%) 27 (17%)
NPI-Q severity [SD] (range) 6.0 [5.1] (0.0–23.0) 6.3 [5.6] (0.0–26.0)
NPI-Q distress [SD] (range) 4.5 [5.5] (0.0–26.0) 5.3 [7.1] (0.0–34.0)
CMAI [SD] (range) 43 [13] (29–87) 45 [16] (29–105)
*Any: any antipsychotic, antidepressant, hypnotic, and/or anxiolytic.
Abbreviations: SD: standard deviation; GDS: Global Deterioration Scale; DSCU: dementia special care unit; NPI-Q:
Neuropsychiatric Inventory – Questionnaire; CMAI: Cohen-Mansfield Agitation Inventory.
Theoretical ranges of instruments: NPI-Q severity: 0–36; NPI-Q distress: 0–60; CMAI: 29–203.
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a variety of symptoms (Smeets et al., 2018). The lack
of correction for neuropsychiatric symptoms may
have contributed to the negative effectiveness.
Third, it is interesting that the current results do
not match the positive findings on the primary
outcome. The PROPER intervention proved to be
effective in improving the appropriateness of the
drug prescriptions (van der Spek et al., 2018a).
This implied that there was an improvement in
the evaluation (i.e. the use of the drug was evaluated
with a specified time frame after the start, and this
was documented in the medical file) and on the
duration (i.e. the duration of use was not longer than
recommended in the guideline, or a dose reduction
was documented in the medical file) (van der Spek
et al., 2015). This illustrates that conscious decisions
Table 2. Results on psychotropic drug prescription and neuropsychiatric symptoms
OBSERVED DSCU MEANS [SD] DIFFERENCE
IN SLOPES PER
6 MONTHS
[95% CI]VARIABLE BASELINE 6 MONTHS 12 MONTHS 18 MONTHS p
...................................................................................................................................................................................................................................................................................................................................
Any psychotropic drug* intervention 50% [20%] 54% [19%] 54% [15%] 55% [13%] 3.9 pp
[0.9–6.9]
0.01
control 50% [17%] 49% [21%] 44% [22%] 42% [16%]
Antipsychotics intervention 27% [22%] 24% [17%] 22% [16%] 26% [15%] 1.3 pp
[− 1.3–4.0]
0.33
control 20% [14%] 19% [15%] 18% [18%] 15% [11%]
Antidepressants intervention 27% [18%] 29% [20%] 29% [16%] 27% [8%] 0.2 pp
[− 2.7–3.1]
0.90
control 24% [13%] 25% [17%] 26% [17%] 22% [16%]
Hypnotics intervention 14% [13%] 17% [11%] 14% [12%] 14% [13%] 1.1 pp
[− 1.2–3.4]
0.37
control 12% [13%] 14% [13%] 11% [14%] 9% [11%]
Anxiolytics intervention 14% [10%] 15% [10%] 16% [11%] 18% [9%] 1.6 pp
[− 0.5–3.6]
0.13
control 15% [11%] 19% [13%] 15% [11%] 14% [12%]
NPI total severity intervention 6.4 [2.9] 5.4 [3.8] 6.5 [3.8] 6.4 [3.0] 0.3
[− 0.2–0.8]
0.24
control 6.3 [2.1] 5.9 [2.3] 5.7 [2.5] 5.4 [2.4]
NPI total distress intervention 5.0 [3.8] 4.0 [3.9] 6.1 [5.7] 5.0 [3.8] 0.1
[− 0.5–0.8]
0.69
control 5.2 [3.3] 5.1 [2.9] 5.6 [3.2] 4.6 [3.3]
CMAI total intervention 44.0 [6.3] 44.1 [8.9] 46.4 [9.9] 46.6 [7.7] 0.6
[− 0.9–2.1]
0.45
control 44.1 [5.7] 43.5 [7.2] 44.0 [7.2] 44.6 [10.4]
*Any: any antipsychotic, antidepressant, hypnotic, and/or anxiolytic.
Abbreviations: SD: standard deviation; CI: confidence interval; pp: percentage point; GDS: Global Deterioration Scale; DSCU: dementia
special care unit; NPI-Q: Neuropsychiatric Inventory – Questionnaire; CMAI: Cohen-Mansfield Agitation Inventory.
Theoretical ranges of instruments: NPI-Q severity: 0–36; NPI-Q distress: 0–60; CMAI: 29–203.
Table 3. Results of the sensitivity analyses
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per individual drug do not necessarily lead to a
reduction in the prescription of psychotropic drugs.
Intervention design
First, the PROPER intervention does not target all
types of factors that contribute to the prescription
of psychotropic drugs. We know from the previ-
ously conducted qualitative part of the PROPER
study that four themes are relevant in the prescrip-
tion process (Smeets et al., 2014). These themes do
not only refer to psychotropic drugs, but also to the
underlying cause for prescription, that is, the neu-
ropsychiatric symptoms: (1) mindset, which com-
prises personal feelings, ideas, and attitudes; (2)
knowledge and experience, which reflect, for
instance, level of training and number of years of
employment; (3) communication and collabora-
tion, covering all interactions between physicians,
nurses, other professionals, and family; and (4)
external possibilities/limitations which comprise
factors on the community level. The PROPER
intervention mainly addresses the knowledge com-
ponent and focuses on psychotropic drugs rather
than on neuropsychiatric symptoms. Indeed, inter-
ventions with a broader scope including improving
communication seemed effective in reducing the
prescription of antipsychotics (Ballard et al., 2009;
Ballard et al., 2016; Tjia et al., 2017), and inter-
ventions that aimed for early detection and treat-
ment of neuropsychiatric symptoms appear more
successful in the reduction of psychotropic drug
use (Rapp et al., 2013; Zwijsen et al., 2014). In
addition, a recent systematic review showed that
psychosocial interventions initiating a culture or
process change in which the physician is involved
are most effective in reducing antipsychotic pre-
scription in nursing homes (Birkenhager-Gillesse
et al., 2018).
Second, the study is conducted in a time frame in
which awareness of the prescription of psychotropic
drugs is already high (Smalbrugge et al., 2008).
Organizations that applied for participation in the
study may have had an even higher awareness,
leaving only a limited window for improvement.
Medication review, including with nurses present,
is increasingly becoming usual care, which makes
the contrast between the intervention and usual care
less profound. This is illustrated by the number of
control organizations that had already conducted
medication reviews in the presence of a nurse.
Counterintuitively, the sensitivity analysis excluding
these three organizations showed that the control
group showed an even larger decline in the prescrip-
tion of any psychotropic drugs. In addition, even
control organizations may benefit from participation
in the trial due to the attention for psychotropic drug
prescription, that is, the Hawthorne effect (Sedg-
wick and Greenwood, 2015).
Strengths of our study are the randomized con-
trolled design and the substantial number of parti-
cipants. However, there were also some limitations.
First, some organizations had a small number of
residents per DSCU, which means that prescription
changes of individual participants and underlying
changes in the case mix could have had a significant
impact on the DSCU’s psychotropic drug preva-
lence rates. The ranges of the number of residents
per DSCU were, however, comparable for the
intervention and control groups, and the composi-
tion with regard to the descriptive variables also
remained similar during the study (results not
shown). Second, we had some baseline imbalances
that may have biased the effects: the stage of
dementia (which was more severe in the interven-
tion population) and the breakdown of the demen-
tia types. The baseline imbalances may have
resulted from the cluster randomization, which is
known to be prone to selection bias and subsequent
baseline imbalances (Bolzern et al., 2018). Both the
stage and type of dementia are expected to be
correlated with the extent of neuropsychiatric
symptoms (Caputo et al., 2008). However, since
there were no relevant baseline imbalances for the
NPI-Q and CMAI scores, we suppose that the
differences in dementia stage and type did not
affect the results. Third, the turnover of physicians
was higher in the intervention group than in the
control group. As staff turnover may affect pre-
scription, this may have influenced the results
(Smeets et al., 2014). Fourth, one intervention
organization did not fully adhere to the intervention
procedures. However, the sensitivity analysis
excluding this organization did not show different
results.
Recent publications in International Psychoger-
iatrics illustrate the complexity to improve prescrip-
tion. Whereas local initiatives such as CHROME
can be very successful and prescription rates may
have declined over time like inNorway (Muniz et al.,
2019; Selbaek et al., 2018), prescription remained
high in other countries like Australia and theNether-
lands (McMaster et al., 2018; van der Spek et al.,
2018b). Aside from prevalence rates, appropriate-
ness of prescription has become an increasingly
important measure (Brimelow et al., 2019; Harrison
et al., 2020; van der Spek et al., 2018b). Further, it
appears that improving prescription involves more
than focusing on medication. An international con-
sensus panel stipulated to search for underlying
causes of neuropsychiatric symptoms and to apply
non-pharmacological interventions including staff
training and environmental changes, prior to pre-
scribing psychotropic drugs (Kales et al., 2019).
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Moreover, interventions that aim to improve pre-
scription should have a broad approach: they should
target not only psychotropic drugs but also skills of
care staff (Ballard and Corbett, 2020). Further, suc-
cessful implementation of interventions to improve
prescription requires a few preconditions on nursing
home level, such as sufficient resources, strong com-
munication, leadership, and management support
(Gerritsen et al., 2019; Groot Kormelinck et al.,
2020).
We conclude that the PROPER intervention
failed to demonstrate effectiveness in reducing the
prevalence of psychotropic drugs. It may be inter-
esting to enrich the intervention with components
that address personal attitudes and communication
between nursing home professionals not only with
respect to the prescription of psychotropic drugs but
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